Kineta completed a reverse merger with Yumanity Therapeutics with Kineta, Inc. as the surviving company effective December 19, 2022.
View Top Employees from Yumanity TherapeuticsWebsite | http://www.kinetabio.com |
Revenue | $5.5 million |
Funding | $46 million |
Employees | 5 (5 on RocketReach) |
Founded | 2014 |
Address | 40 Guest St Ste 4410, Boston, Massachusetts 02135, US |
Phone | (617) 409-5300 |
Technologies |
JavaScript,
HTML,
PHP
+11 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Biotechnology, Business Services, Science and Engineering, Health Care, Therapeutics |
Web Rank | 13 Million |
Keywords | C4 Therapeutics, Yumanity Therapeutics, Tony Coles Onyx, Yumanity, Reports On Yumanity Therapeutics |
Competitors | Alkahest, Inc., Alzheon, Inc. | Preserving Future Memories, Cognition Therapeutics, Inc., Diffusion Pharmaceuticals, Leap Therapeutics |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 541714 Companies, NAICS Code 541 Companies, NAICS Code 54171 Companies |
Looking for a particular Yumanity Therapeutics employee's phone or email?
The Yumanity Therapeutics annual revenue was $5.5 million in 2024.
Tony Coles is the Chairman of Yumanity Therapeutics.
5 people are employed at Yumanity Therapeutics.
Yumanity Therapeutics is based in Boston, Massachusetts.
The NAICS codes for Yumanity Therapeutics are [5417, 54, 541714, 541, 54171].
The SIC codes for Yumanity Therapeutics are [873, 87].